case_images: PMC2750244_01
case_images: Computed tomography scan before and after treatment with gefitinib. Reproduced with permission from: Cappuzzo F, Calandri C, Bartolini S, Crino L (2003b).
case_images: 89-6601478f1.jpg
case_images: PMC2750244_01_89-6601478f1.jpg
case_images: fig1
case_images: The complete response in the brain was observed 6 weeks after treatment with gefitinib started in a patient who had completed whole-brain radiotherapy 3 months prior to the beginning of gefitinib (Figure 1).
case_images: Case history of a patient with NSCLC and brain metastases taking gefitinib. Data previously presented by: van Zandwijk N. Risk/benefit of gefitinib ('Iressa', ZD1839). Oral presentation at the ICE meeting, Madrid, June 2003. Used with permission.
case_images: 89-6601478f2.jpg
case_images: PMC2750244_01_89-6601478f2.jpg
case_images: fig2
case_images: ICE meeting showed good tolerance of concurrent gefitinib and radiotherapy (van Zandwijk [b], ICE abs, personal communication). In this case study, a 55-year-old male exsmoker with stage IV NSCLC and multiple pulmonary (lymphangitic) metastases developed multiple brain metastases (approximately 20 small lesions) after receiving treatment with gefitinib for >1 year (Figure 2).
case_images: Computed tomography scan before and after treatment with gefitinib and radiotherapy (case history shown in Figure 2). Previously presented by: van Zandwijk N. Risk/benefit of gefitinib ('Iressa', ZD1839). Oral presentation at the ICE meeting, Madrid, June 2003. Reproduced with permission.
case_images: 89-6601478f3.jpg
case_images: PMC2750244_01_89-6601478f3.jpg
case_images: fig3
case_images: Delayed imaging 9 months later showed almost complete resolution of the brain metastases (Figure 3).